Bay Street News

ResMed’s 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and other chronic diseases, today announced the results of its 2024 Global Sleep Survey in conjunction with World Sleep Day (March 15), shedding light on the critical sleep challenges faced by people around the world.

The survey uncovered a staggering number of people suffering from a chronic lack of good sleep, with nearly 40% of respondents getting no more than three nights of good sleep each week – and some individuals reporting just one. Respondents reported feeling excessive daytime sleepiness (50%), negative feelings in the morning (40%) and more irritable (39%).

In its fourth year, the survey is core to ResMed’s Discover Your Sleep Superpowers campaign and this year’s findings are even more comprehensive, with 36,000 participants across 17 markets providing insights on the state of sleep around the world.

A world in sleep crisis*

Discover your sleep superpowers

“With sleep being the third pillar of health, alongside diet and exercise, prioritizing your sleep is one of the most effective ways to improve your overall health,” said Carlos, M. Nunez. M.D., ResMed Chief Medical Officer. “With over 936 million people around the world affected by sleep apnea1, it is concerning to learn that 40% of the people we surveyed get no more than three good nights of sleep a week. Poor sleep can be an indicator of conditions such as insomnia and sleep apnea, so this World Sleep Day we want to empower people to take charge of their sleep health and have conversations with their healthcare provider.”

Among survey respondents, 57% claim they are aware of sleep apnea, a chronic disease in which the muscles of the throat relax to the point of collapse, restricting airflow and causing the sufferer to stop breathing repeatedly throughout the night. Notably, however, only 26% of those respondents have been diagnosed.

To learn more about ResMed’s 2024 Global Sleep Survey or for help identifying if you have symptoms that could indicate poor sleep health, visit https://www.resmed.com/sleepassessment.

Survey Methodology

The 2024 ResMed Global Sleep Survey included a total of 36,000 respondents across 17 markets including Australia, Brazil, China, France, Germany, Hong Kong, India, Ireland, Japan, Korea, Mexico, New Zealand, Singapore, Taiwan, Thailand, UK and USA, between December 2023 and January 2024.

About ResMed

At ResMed we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

Contacts

For media                                                                                
+1 858.289.7272                                                        
news@resmed.com                                                        

For investors
+1 858.836.5000
investorrelations@resmed.com   

1 Benjafield A et al. Lancet Respir Med 2019)
*Based on 36,000 respondents across 17 markets surveyed as part of the ResMed 2024 Global Sleep Survey between December 2023 and January 2024


Bay Street News